HOD HASHARON, Israel, March 5, 2018 /PRNewswire/ — Wize Pharma, Inc. (OTCQB: WIZP), a clinical-stage biopharmaceutical company currently focused on the treatment of ophthalmic disorders, today announced the Company’s previously approved 1-for-24 reverse split of its common stock will…
